$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022014057 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$17.26M	$17.76M	$14.68M
YoY Change	17.54%	14.94%	2.36%
Cost Of Revenue	$6.727M	$6.891M	$5.449M
YoY Change	23.45%	14.47%	-9.7%
Gross Profit	$10.53M	$10.87M	$9.234M
YoY Change	14.06%	15.37%	11.11%
Gross Profit Margin	61.02%	61.2%	62.89%
Selling, General & Admin	$17.19M	$15.14M	$15.81M
YoY Change	8.71%	4.33%	19.03%
% of Gross Profit	163.18%	139.3%	171.2%
Research & Development	$1.078M	$1.045M	$787.0K
YoY Change	36.98%	5.56%	-14.36%
% of Gross Profit	10.24%	9.62%	8.52%
Depreciation & Amortization	$201.0K	$262.0K	$221.0K
YoY Change	-9.05%	-6.43%	3.27%
% of Gross Profit	1.91%	2.41%	2.39%
Operating Expenses	$18.26M	$16.18M	$16.60M
YoY Change	10.05%	4.35%	16.87%
Operating Profit	-$7.732M	-$5.316M	-$7.362M
YoY Change	5.03%	-12.71%	24.99%
Interest Expense	$8.000K	-$9.000K	$19.00K
YoY Change	-57.89%	-55.0%	58.33%
% of Operating Profit
Other Income/Expense, Net			-$19.00K
YoY Change			58.33%
Pretax Income	-$7.740M	-$5.325M	-$7.380M
YoY Change	4.88%	-12.7%	25.08%
Income Tax
% Of Pretax Income
Net Earnings	-$7.740M	-$5.325M	-$7.381M
YoY Change	4.86%	-12.7%	25.06%
Net Earnings / Revenue	-44.85%	-29.98%	-50.27%
Basic Earnings Per Share	-$0.11		-$0.12
Diluted Earnings Per Share	-$0.11	-$77.96K	-$0.12
COMMON SHARES
Basic Shares Outstanding	68.31M shares	68.29M shares	64.16M shares
Diluted Shares Outstanding	68.31M shares		64.16M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.79M	$28.22M	$44.69M
YoY Change	-53.47%	68.98%	228.36%
Cash & Equivalents	$21.00M	$28.22M	$44.69M
Short-Term Investments
Other Short-Term Assets	$2.113M	$1.859M	$1.120M
YoY Change	88.66%	61.65%	60.0%
Inventory	$15.31M	$13.60M	$12.76M
Prepaid Expenses
Receivables	$6.310M	$5.226M	$3.350M
Other Receivables	-$2.300M	$2.100M	$1.300M
Total Short-Term Assets	$44.52M	$48.91M	$63.22M
YoY Change	-29.57%	51.79%	116.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.993M	$7.355M	$3.058M
YoY Change	128.68%	129.41%	-30.66%
Goodwill
YoY Change
Intangibles	$808.0K	$857.0K	$1.022M
YoY Change	-20.94%	-20.79%
Long-Term Investments
YoY Change
Other Assets	$606.0K	$723.0K	$594.0K
YoY Change	2.02%	15.68%	-25.75%
Total Long-Term Assets	$8.407M	$8.935M	$5.774M
YoY Change	45.6%	45.54%	-10.62%
TOTAL ASSETS
Total Short-Term Assets	$44.52M	$48.91M	$63.22M
Total Long-Term Assets	$8.407M	$8.935M	$5.774M
Total Assets	$52.93M	$57.84M	$68.99M
YoY Change	-23.28%	50.79%	93.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.780M	$10.42M	$11.69M
YoY Change	-16.36%	10.35%	43.3%
Accrued Expenses	$8.126M	$6.481M	$7.328M
YoY Change	10.89%	5.67%	25.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.00K	$20.00K	$20.00K
YoY Change	-15.0%	-33.33%	-90.48%
Total Short-Term Liabilities	$18.69M	$17.61M	$19.76M
YoY Change	-5.38%	6.9%	36.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$20.00K
YoY Change	-100.0%	-100.0%	-50.0%
Other Long-Term Liabilities	$8.359M	$8.500M	$5.390M
YoY Change	55.08%	56.25%	18.2%
Total Long-Term Liabilities	$8.359M	$8.500M	$5.410M
YoY Change	54.51%	55.68%	17.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.69M	$17.61M	$19.76M
Total Long-Term Liabilities	$8.359M	$8.500M	$5.410M
Total Liabilities	$27.05M	$26.11M	$25.16M
YoY Change	7.52%	19.05%	32.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.7M	-$169.0M
YoY Change		19.13%
Common Stock	$68.00K	$68.00K
YoY Change		9.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.88M	$31.73M	$43.83M
YoY Change
Total Liabilities & Shareholders Equity	$52.93M	$57.84M	$68.99M
YoY Change	-23.28%	50.79%	93.74%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$7.740M	-$5.325M	-$7.381M
YoY Change	4.86%	-12.7%	25.06%
Depreciation, Depletion And Amortization	$201.0K	$262.0K	$221.0K
YoY Change	-9.05%	-6.43%	3.27%
Cash From Operating Activities	-$7.200M	-$4.944M	-$5.405M
YoY Change	33.21%	-24820.0%	3.52%
INVESTING ACTIVITIES
Capital Expenditures	-$25.00K	-$2.000K	-$50.00K
YoY Change	-50.0%	-106.67%	150.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$25.00K	-$2.000K	-$46.00K
YoY Change	-45.65%	-120.0%	130.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$24.87M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$3.000K	63.00K	$33.45M
YoY Change	-100.01%	-94.66%	90291.89%
NET CHANGE
Cash From Operating Activities	-$7.200M	-4.944M	-$5.405M
Cash From Investing Activities	-$25.00K	-2.000K	-$46.00K
Cash From Financing Activities	-$3.000K	63.00K	$33.45M
Net Change In Cash	-$7.226M	-4.883M	$27.99M
YoY Change	-125.81%	-503.55%	-637.93%
FREE CASH FLOW
Cash From Operating Activities	-$7.200M	-$4.944M	-$5.405M
Capital Expenditures	-$25.00K	-$2.000K	-$50.00K
Free Cash Flow	-$7.175M	-$4.942M	-$5.355M
YoY Change	33.99%	49320.0%	2.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001386570
CY2022Q1	us-gaap	Gross Profit GrossProfit	10532000	USD
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37752
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CHROMADEX CORPORATION
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2940963
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10900 Wilshire Blvd
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2022Q1	dei	City Area Code CityAreaCode	310
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	388-6706
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	CDXC
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68334586	shares
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28219000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18694000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	54000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	65000	USD
CY2022Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2300000	USD
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2100000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6310000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5226000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	15307000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13601000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1913000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1859000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	44523000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	48905000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2940000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3003000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	808000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	857000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4053000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4352000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	606000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	723000	USD
CY2022Q1	us-gaap	Assets Assets	52930000	USD
CY2021Q4	us-gaap	Assets Assets	57840000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9780000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10423000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8126000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6481000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	630000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	528000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	17000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	20000	USD
CY2022Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	141000	USD
CY2021Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	161000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17613000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4346000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4346000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4013000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4154000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	27053000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	26113000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68149000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68149000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68126000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68126000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202502000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200614000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176693000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168953000	USD
CY2022Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	0	USD
CY2021Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-2000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25877000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	31727000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52930000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57840000	USD
CY2022Q1	us-gaap	Revenues Revenues	17259000	USD
CY2021Q1	us-gaap	Revenues Revenues	14683000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	6727000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	5449000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q1	us-gaap	Gross Profit GrossProfit	9234000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8237000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6258000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1078000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	787000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8949000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9551000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18264000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	16596000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7732000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7362000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	8000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	19000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68314000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68314000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64164000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64164000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	31727000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1888000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25877000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16424000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000	USD
CY2021Q1	cdcx	Issuance Of Common Stock Net Of Offering Costs Amount IssuanceOfCommonStockNetOfOfferingCostsAmount	24871000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8633000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1284000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	43832000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	201000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	221000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	60000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	299000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	126000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1284000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-28000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1094000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1967000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1079000	USD
CY2022Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	114000	USD
CY2021Q1	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	28000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-46000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-643000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2248000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1645000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1196000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-47000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-154000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7198000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5405000	USD
CY2022Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	25000	USD
CY2021Q1	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	46000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24871000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8633000	USD
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	44000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33445000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7226000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27994000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28219000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16697000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20993000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44691000	USD
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	USD
CY2021Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	58000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	154000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of BusinessChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex”, the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. The Company further develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company also offers natural product fine chemicals, known as phytochemicals, and related research and development services.
CY2022Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications: Certain prior period results have been reclassified to be consistent with the current period presentation.
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7200000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21000000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7740000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7381000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68314000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68314000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64164000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64164000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	356000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	0	shares
CY2022Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2021Q1	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2022Q1	us-gaap	Revenues Revenues	17259000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	6727000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	10532000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8237000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1078000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8949000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18264000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7732000	USD
CY2021Q1	us-gaap	Revenues Revenues	14683000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	5449000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	9234000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6258000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	787000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9551000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	16596000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7362000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4600000	USD
CY2022Q1	us-gaap	Revenues Revenues	17259000	USD
CY2021Q1	us-gaap	Revenues Revenues	14683000	USD
CY2022Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2600000	USD
CY2021Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1600000	USD
CY2022Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2300000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2131000	USD
CY2022Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	530000	USD
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2100000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7383000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6823000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4323000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4131000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3071000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	516000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	15307000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13601000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	256000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	256000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	154000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	40000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	40000	USD
CY2022Q1	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	296000	USD
CY2021Q1	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	194000	USD
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	64000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	62000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	360000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	620000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	949000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1159000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1141000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	906000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	498000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	179000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5452000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	809000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4643000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	630000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4013000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.765
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Price SharePrice	2.46
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	10100000	USD
CY2021Q4	cdcx	Unvested Shares UnvestedShares	115000	shares
CY2021Q4	cdcx	Unvested Weighted Average Fair Value UnvestedWeightedAverageFairValue	10.21
CY2022Q1	cdcx	Unvested Shares Granted UnvestedSharesGranted	272000	shares
CY2022Q1	cdcx	Unvested Weighted Average Fair Value Granted UnvestedWeightedAverageFairValueGranted	2.66
CY2022Q1	cdcx	Unvested Shares Vested UnvestedSharesVested	23000	shares
CY2022Q1	cdcx	Unvested Weighted Average Fair Value Vested UnvestedWeightedAverageFairValueVested	11.83
CY2022Q1	cdcx	Unvested Shares Forfeited UnvestedSharesForfeited	8000	shares
CY2022Q1	cdcx	Unvested Weighted Average Fair Value Forfeited UnvestedWeightedAverageFairValueForfeited	11.83
CY2022Q1	cdcx	Unvested Shares UnvestedShares	356000	shares
CY2022Q1	cdcx	Unvested Weighted Average Fair Value UnvestedWeightedAverageFairValue	4.28
CY2022Q1	cdcx	Unvested Shares Expected To Vest UnvestedSharesExpectedToVest	356000	shares
CY2022Q1	cdcx	Unvested Weighted Average Fair Value Expected To Vest UnvestedWeightedAverageFairValueExpectedToVest	4.28
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1888000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1284000	USD
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	USD

Files In Submission

Name	View Source	Status
0001628280-22-014057-index-headers.html	Edgar Link	pending
0001628280-22-014057-index.html	Edgar Link	pending
0001628280-22-014057.txt	Edgar Link	pending
0001628280-22-014057-xbrl.zip	Edgar Link	pending
cdcx-20220331.htm	Edgar Link	pending
cdcx-20220331.xsd	Edgar Link	pending
cdcx-20220331_cal.xml	Edgar Link	unprocessable
cdcx-20220331_def.xml	Edgar Link	unprocessable
cdcx-20220331_g1.jpg	Edgar Link	pending
cdcx-20220331_htm.xml	Edgar Link	completed
cdcx-20220331_lab.xml	Edgar Link	unprocessable
cdcx-20220331_pre.xml	Edgar Link	unprocessable
cdxcq1202210qex-311.htm	Edgar Link	pending
cdxcq1202210qex-312.htm	Edgar Link	pending
cdxcq1202210qex-321.htm	Edgar Link	pending
ex101-dartmouthcollegetrus.htm	Edgar Link	pending
ex102-dartmouthcollegetrus.htm	Edgar Link	pending
ex103-dartmouthcollegetrus.htm	Edgar Link	pending
ex104-dartmouthcollegetrus.htm	Edgar Link	pending
ex105-firstamendmenttouniv.htm	Edgar Link	pending
ex106-universityqueensofbe.htm	Edgar Link	pending
ex107-transitionandseparat.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2022 Q1 Form 10-Q Financial Statement

#000162828022014057 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2022 Q1 Form 10-Q Financial Statement

#000162828022014057 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc